Skip to main content
Mezzion Pharma Co., Ltd. logo

Mezzion Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 140410 ISIN · KR7140410002 KO Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2026-05-22 Capital/Financing Update
Country KR South Korea
Listing KO 140410

About Mezzion Pharma Co., Ltd.

https://mezzion.com

Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare diseases. The company's primary efforts are concentrated on addressing the unmet medical needs of individuals with a Fontan circulation, a palliative surgical procedure for single-ventricle heart defects. Its lead drug candidate, udenafil, is being advanced as a potential first-to-market treatment to improve the physiology of the Fontan circulation. Mezzion is conducting late-stage clinical development, including a confirmatory Phase 3 trial (FUEL-2), to evaluate the therapy's efficacy in adolescent patients.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기전환사채만기전취득결정)
Capital/Financing Update Classification · 84% confidence The document is a Korean “주요사항보고서” (Report on Major Matters) disclosing the company's decision to acquire its own privately placed convertible bonds (self-convertible bonds) prior to maturity. This is an update on the company's financing activities and entails a change in its capital structure (debt repurchase). It is not an earnings release, management discussion, or annual/interim report, nor is it a share buyback of equity. Therefore, it best fits the Capital/Financing Update category.
2026-05-22 Korean
주요사항보고서(자기전환사채만기전취득결정)
Regulatory Filings Classification · 55% confidence The document is a Korean “주요사항보고서” (Major Event Report) filed with the Financial Services Commission and stock exchange, announcing the company’s decision to pre-maturity acquire its own convertible bonds. It contains no full financial statements or investor presentation materials but is a regulatory filing notifying a significant capital structure event. This falls under general Regulatory Filings (RNS) as it does not match more specific categories (e.g., share repurchase is for shares, not debt instruments; not an earnings release, dividend notice, or board change).
2026-05-22 Korean
소송등의제기ㆍ신청(일정금액이상의청구)
Legal Proceedings Report Classification · 92% confidence The document is a Korean stock exchange disclosure titled “소송등의제기ㆍ신청(일정금액 이상의 청구)” describing the filing of an appeal in a damages lawsuit, including case number, claim amount, court, and planned legal response. It is a company announcement regarding a material legal proceeding. This aligns exactly with the “Legal Proceedings Report” category (LTR).
2026-05-21 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is clearly titled “분기보고서 (제25기 1분기)” covering the period January 1, 2026 to March 31, 2026, filed with the Financial Services Commission and Korea Exchange. It includes extensive narrative on business overview, product pipeline, research & development activities, and detailed financial tables for the quarter and prior periods. This meets the definition of a comprehensive interim/quarterly report with substantive financial data and analysis. Therefore, it is classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
증권발행결과(자율공시) (제6회차 CB)
Capital/Financing Update Classification · 90% confidence The document is a voluntary disclosure of the terms and results of the company’s issuance of the 6th series convertible bonds. It details the amount raised, issuance method, board resolution date, and settlement date—clearly an update on the company’s fundraising/financing activity. This aligns with “Capital/Financing Update (CAP)”.
2026-05-12 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 92% confidence The document is a "주요사항보고서(전환사채권 발행결정)" filed with the Financial Supervisory Service/Korea Exchange, detailing the decision to issue KRW 36.5 billion of convertible bonds, including terms, interest rates, conversion price, put and call options, and underwriting arrangements. This is an update on the company’s financing and capital structure. It is not an earnings release, management discussion, or a proxy statement but a financing event disclosure. Therefore, it should be classified as a Capital/Financing Update (CAP).
2026-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.